TrialThe oncologist2020

Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.

Zongyang Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.